CyPath® Lung Diagnostic Helps Defer Unnecessary Biopsy

Case study shows noninvasive test supported physician's assessment, prompted follow-up imaging, and avoided risky procedure

Apr. 15, 2026 at 4:04am

Got story updates? Submit your updates here. ›

A translucent X-ray image revealing the intricate internal structure of a human lung, with glowing lines and ghostly details against a dark background, conceptually representing the advanced technology behind a noninvasive diagnostic test for lung disease.A noninvasive diagnostic test helps physicians make informed decisions about managing patients with suspicious lung nodules, avoiding unnecessary and risky procedures.San Antonio Today

A case study released by bioAffinity Technologies highlights how the company's noninvasive CyPath® Lung diagnostic test helped a high-risk patient avoid an unnecessary and risky biopsy. Standard imaging and risk models initially suggested a high likelihood of lung cancer in the patient, but the CyPath® Lung test affirmed the physician's assessment that the nodule was likely due to inflammation, not cancer. A follow-up scan confirmed the nodule had resolved, demonstrating the value of CyPath® Lung in providing objective data to guide patient management decisions.

Why it matters

This case illustrates how CyPath® Lung can assist physicians in managing patients with pulmonary nodules, particularly those with underlying lung disease or other complicating health conditions. By providing additional objective data, CyPath® Lung can help physicians confidently defer unnecessary and often risky invasive procedures like biopsies.

The details

The patient, a 70-year-old female with a history of smoking and emphysema, presented with increased respiratory symptoms. Imaging revealed a 30-millimeter pulmonary nodule and enlarged lymph nodes, suggesting a high likelihood of lung cancer. However, the treating pulmonologist, Dr. Daya Nadarajah, ordered the CyPath® Lung test, which returned a 'Unlikely Malignancy' result. This prompted a follow-up CT scan that showed the nodule had completely resolved, confirming Dr. Nadarajah's assessment that the abnormality was due to inflammation, not cancer.

  • The patient presented with the suspicious pulmonary nodule.
  • CyPath® Lung test was ordered and returned a 'Unlikely Malignancy' result.
  • A follow-up CT scan showed the nodule had resolved.

The players

bioAffinity Technologies, Inc.

A biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, including the CyPath® Lung test.

Daya Nadarajah, MD

The treating pulmonologist who ordered the CyPath® Lung test for the patient.

Gordon Downie, MD, PhD

The Chief Medical Officer of bioAffinity Technologies.

Got photos? Submit your photos here. ›

What they’re saying

“In this case, imaging findings and risk calculators suggested a very high probability of lung cancer, and we scheduled her for biopsy. I routinely use CyPath® Lung in my practice and ordered the test for her. She received a negative result, 'Unlikely Malignancy,' which prompted another scan before we moved forward with the biopsy.”

— Daya Nadarajah, MD, Treating Pulmonologist

“In patients with underlying lung disease, like emphysema, or other comorbidities like cardiovascular disease, biopsy can carry significant risks. Physicians must weigh the risks against the potential benefits. Adding CyPath® Lung to the diagnostic pathway for indeterminate nodules provides additional objective data that can be very valuable when assessing patients with complicating health conditions.”

— Gordon Downie, MD, PhD, Chief Medical Officer, bioAffinity Technologies

What’s next

The case study highlights how CyPath® Lung can assist physicians in managing patients with pulmonary nodules, helping to avoid unnecessary and risky procedures like biopsies. bioAffinity Technologies plans to continue promoting the clinical utility of CyPath® Lung to support physicians in making informed decisions about patient care.

The takeaway

This case demonstrates the value of CyPath® Lung in providing objective data to complement imaging and risk models, empowering physicians to confidently defer invasive procedures when appropriate. By incorporating CyPath® Lung into the diagnostic pathway, physicians can improve patient care and avoid exposing high-risk individuals to the potential complications of unnecessary biopsies.